Dilaforette is Granted SEK 2.85m from Vinnova
News Nov 06, 2012
Dilaforette has announced that it has been granted SEK 2.85m from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria.
Sevuparin is intended as an adjunctive therapy to anti-parasite medicines in order to prevent the infected red blood cells from obstructing blood vessels and thereby reducing mortality.
Each year nearly 10 million people are diagnosed with severe malaria and about one million die of the disease.
The grant from Vinnova will be used for process and method development and validation. The project is in Phase II with a clinical study ongoing in Thailand in collaboration with leading malaria clinicians at the Mahidol Oxford Tropical Medicine Research Unit, which is supported by the Wellcome Trust.
“We are very pleased that sevuparin was selected by Vinnova, in high competition. The additional funding will take sevuparin one step further towards a treatment of severe malaria, a disease where more efficacious medications are urgently needed”, says Pirkko Sulila Tamsen, CEO of Dilaforette.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019